Anxiety, Depression a Problem for School-age Patients in China
School-age children and adolescents with spinal muscular atrophy (SMA) in China experience a high rate of anxiety and depression,…
Articles by Steve Bryson, PhD
Cure SMA Advocates for Better Wheelchair Storage for Air Travel
In a letter to a U.S. Department of Transportation Advisory Committee, Cure SMA called for better wheelchair handling…
Canadian Agency Favors Zolgensma Only for Babies Up to 6 Months Old
The Canadian Agency for Drugs and Technologies in Health (CADTH) will not recommend reimbursement for Zolgensma in children with…
Low Bone Density Puts SMA Children in China at Risk for Fractures
Children with spinal muscular atrophy (SMA) type 2 or 3 in China have lower bone mineral density — putting…
Certain Abilities Decline in SMA Type 3 Children Unable to Walk
Lung function and upper limb abilities worsened over a two-year period in young people with spinal muscular atrophy (SMA) type…
Mothers Want to Improve Children’s Quality of Life
Mothers of children and adolescents with spinal muscular atrophy (SMA) want to find ways to improve the quality of…
Zolgensma Helps Mobility of SMA Children in Qatari Real-world Study
The gene therapy Zolgensma safely improved mobility in young children with spinal muscular atrophy (SMA) living in Qatar,…
Early Work Supports Apitegromab’s Safety as SMA Muscle Therapy
A series of toxicology studies in rats and macaque monkeys confirmed the safety and tolerability of apitegromab, an investigational…
US Pediatricians Often Overlook Steps in Diagnosing SMA, Surveys Show
Many U.S. pediatricians fail to use developmental screening tools and are not familiar with the diagnostic requirements for spinal…
Major Developmental Milestones Met in Infants, Zolgensma Data Show
New data about Zolgensma, the one-time gene therapy for children with spinal muscular atrophy (SMA), demonstrate age-appropriate development when…